Gray GC, McPhate DC, Leinonen M, Cassell GH, Deperalta EP, Putnam SD, Karcher JA, Sawyer MH, Laurila A, Connor JD, 1998. Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease. Clin Infect Dis 26: 103–110.
Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, Elliott J, Hyde T, Schuchat A, Gaynor B, Dowell SF, 2002. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 35: 395–402.
Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S, 2012. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J 31: 341–346.
Haug S et al.., 2010. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 51: 571–574.
Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S, 2013. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 56: 1519–1526.
West SK, Munoz B, Weaver J, Mrango Z, Dize L, Gaydos C, Quinn TC, Martin DL, 2016. Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey. PLoS Negl Trop Dis 10: e0004352.
CLSI, 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. Wayne, PA: CLSI document M100-S24.
Seidman JC, Coles CL, Silbergeld EK, Levens J, Mkocha H, Johnson LB, Munoz B, West SK, 2014. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol 43: 1105–1113.
Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A, 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52: 145–148.
Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD, 1997. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 24: 356–362.
Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, Safari S, Sam NE, Everett D, Mabey DC, Gillespie SH, 2003. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 47: 2765–2769.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||466||136||9|
Mass administration of azithromycin (MDA) is integral to trachoma control. Recent studies suggest that MDA may increase drug-resistant pathogens, yet findings from prior studies suggest little long-term impact on resistance. This disparity may be linked to differences in pre-MDA community-level resistance patterns. We describe carriage prevalence and antibiotic resistance patterns for Streptococcus pneumoniae (Spn) (nasopharyngeal swab collection), Staphylococcus aureus (SA) (nasopharyngeal swabs), and Escherichia coli (EC) (rectal swabs) in 1,047 children ages 1–59 months in a district with MDA cessation 4 years ago. Antibiotic susceptibility was evaluated by disk diffusion and Etest. The carriage rates for Spn, SA, and EC were 43.5% (455/1,047), 13.2% (138/1,047), and 61.7% (646/1,047), respectively. Resistance to AZM was observed in 14.3%, 29.0%, and 16.6% of the Spn, SA, and EC isolates, respectively. Spn resistance was variable (0–67%) by hamlet. Future analyses will assess the influence of pre-MDA antibiotic resistance patterns on those observed following MDA.
Financial support: This study was made possible by a grant from the Bill & Melinda Gates Foundation (OPP1032340).
Authors’ addresses: Evan M. Bloch, Department of pathology, Johns Hopkins Medicine, Baltimore, MD, E-mail: firstname.lastname@example.org. Sheila K. West, Jerusha Weaver, and Beatriz Munoz, Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com. Kasubi Mabula, Department of Microbiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, E-mail: firstname.lastname@example.org. Zakayo Mrango, National Institute for Medical Research, Kilosa, Tanzania, E-mail: email@example.com. Thomas Lietman, Proctor Foundation, University of California San Francisco, San Francisco, CA, E-mail: firstname.lastname@example.org. Christian Coles, Preventative Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, E-mail: email@example.com.